RxDoctor Payments Data

Alan Zalkowitz, MD

Rheumatology · Franklin Lakes, NJNPI 1760487938

Payments from drug & device makers

$3,076in general payments, 2019–2025

Across 162 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$496
  • AbbVie$378
  • Novartis$326
  • Johnson & Johnson$323
  • UCB, Inc.$271
  • Pfizer$215
  • plus $1K from 28 others

What the payments were for

  • Food & beverage$3,00698%
  • Education$702%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,076 in reported general payments places this provider in the 50th percentile of 234 rheumatology providers in New Jersey.

See all rheumatology providers in New Jersey

Medicare billing

Part B allowed, 2024
$420,513
Medicare patients
172
Services billed
23,030

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RayosPrednisone31$143,678
OtezlaApremilast12$55,776
RasuvoMethotrexate/Pf13$19,746
SavellaMilnacipran Hcl24$17,747
Hydroxychloroquine Sulfate187$8,657
Colchicine133$7,926
Duloxetine Hcl114$3,257
ValacyclovirValacyclovir Hcl38$2,637
Prednisone157$2,353
Celecoxib91$2,350
MethotrexateMethotrexate Sodium106$2,097
Famotidine33$1,307
Gabapentin49$1,193
Allopurinol84$1,180
Methylprednisolone53$1,151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenRayos, Otezla$496$199,45443 claims
AbbVieSavella$378$17,74724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 234 rheumatology providers in New Jersey.

Other rheumatology in Franklin Lakes

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →